NASDAQ:CLRB - Cellectar Biosciences, Inc.
$2.13
 $0.03
+1.43%
4:00PM EDT
2019-07-22
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., incorporated on June 24, 1996, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company's research and development program is based on its PDC cancer targeting delivery platform. Its platform helps in discovery and development of a range of cancer targeting agents. The Company's pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, CLR 125, CLR 124, CLR 1502 and CTX Product Portfolio.CLR 131The Company's CLR 131 is a small-molecule, broad-spectrum and cancer-targeting radiotherapeutic PDC that is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells. CLR 131 is its lead PDC radiotherapeutic product candidate in Phase 1 study for the treatment of relapse or refractory multiple myeloma. Its CLR 131 consists of its PLE, 18-(p-[I-124] iodophenyl) octadecyl phosphocholine acting as a cancer-targeting delivery and retention vehicle, covalently labeled with iodine-131, a cytotoxic (cell-killing) radioisotope.CLR 125The Company's CLR 125 is a broad-spectrum, cancer-targeting and radiotherapeutic under pre-clinical investigation for the treatment of micro metastatic disease. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CLRB     avg for
industry  
  avg for
sector  
42 stocks weight:  18. 22   0. 00   0. 00  
42 stocks rank:  3. 42 K 1. 35 K 799. 74  
# analyst opinions:  2. 00   12. 76   13. 14  
mean recommendation:  1. 50   2. 11   2. 07  

quick ratio:  4. 77   5. 61   1. 85  
current ratio:  5. 04   6. 00   2. 31  

target price low:  2. 04   75. 88   108. 31  
target price avg:  4. 00   97. 27   130. 10  
target price high:  5. 20   124. 58   149. 02  
1-yr high:  6. 53   104. 89   135. 09  
last close:  2. 13   79. 79   118. 76  
50-day avg:  2. 18   79. 39   116. 18  
200-day avg:  2. 21   81. 61   114. 52  
1-yr low:  1. 29   62. 76   94. 70  
volume:  121. 53 K 2. 99 M 4. 43 M
50-day avg volume:  573. 91 K 3. 39 M 4. 22 M
200-day avg volume:  240. 07 K 3. 13 M 4. 83 M

1-day return:  1. 43 % 0. 33 % 0. 14 %
this week return:  1. 43 % 0. 33 % 0. 14 %
12-wk return:  -11. 98 % 1. 00 % 3. 51 %
52-wk return:  -67. 91 % 0. 58 % 10. 25 %

enterprise value (EV):  3. 06 M 44. 78 B 115. 63 B
market cap:  20. 01 M 38. 01 B 103. 29 B
EBITDA:  -11. 73 M 4. 47 B 7. 73 B
enterprise multiple (EV/EBITDA):  -0. 26   2. 11   11. 26  
total debt:  599. 90 K 11. 72 B 16. 76 B
debt/equity:  6. 09   61. 22   124. 43  
net income (common):  -15. 63 M 2. 06 B 3. 79 B

shares outstanding:  5. 32 M 562. 08 M 1. 27 B
shares:  4. 30 M 573. 33 M 1. 26 B
shares short:  390. 75 K 11. 60 M 12. 29 M
shares short prior month:  390. 38 K 9. 81 M 12. 46 M
short ratio:  2. 60   5. 88   3. 41  
short % of float:  7. 80 % 6. 88 % 2. 72 %
total cash/share:  1. 97   10. 62   8. 83  
total cash:  10. 49 M 6. 17 B 5. 72 B
free cash flow:  -6. 71 M 3. 08 B 3. 10 B
operating cash flow:  -11. 07 M 3. 99 B 4. 08 B

book value:  1. 58   12. 74   26. 25  
price/book:  1. 34   4. 38   9. 01  
operating margins:  0. 00 % -319. 65 % -29. 05 %
EBITDA margins:  0. 00 % 11. 82 % 24. 13 %
profit margins:  0. 00 % 5. 62 % 14. 29 %
gross margins:  0. 00 % 34. 75 % 57. 07 %

1-yr max volatility:  36. 87 % --- ---
1-yr mean volatility:  3. 80 % 1. 95 % 1. 25 %

1-yr EPS:  -4. 18   1. 58   3. 82  
forward EPS:  -1. 26   3. 16   6. 65  
P/E:  -0. 51   0. 21   31. 97  
forward P/E:  -1. 67   4. 95   15. 14  
PE/G:  0. 01   0. 74   0. 13  
growth:  -47. 36 % 295. 81 % 85. 47 %
earnings high:  -0. 60   0. 84   1. 56  
earnings avg:  -0. 69   0. 65   1. 45  
earnings low:  -0. 79   0. 40   1. 35  
revenue high:  -0. 00   2. 70 B 8. 76 B
revenue avg:  -0. 00   2. 64 B 8. 62 B
revenue low:  -0. 00   2. 58 B 8. 45 B
return on assets:  -66. 89 % -3. 43 % 4. 51 %
return on equity:  -154. 75 % -104. 30 % 140. 44 %

beta (1yr vs S&P500):  1. 41   1. 27   0. 91  
sharpe (1yr):  -0. 76   0. 20   0. 80  

held % insiders:  3. 46 % 6. 63 % 3. 46 %
held % institutions:  8. 07 % 76. 45 % 67. 87 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-22 : CLRB
.    101.272 =       101.272 :: --> INITIAL WEIGHT <--
.    - 4.184 =        97.088 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.197 =       213.336 :: P/E factor
.    x 2.209 =       471.251 :: PE/G factor
.    x 1.711 =       806.424 :: beta factor
.    x 0.913 =        736.02 :: sharpe factor
.     x 2.84 =      2090.436 :: current ratio factor
.    x 1.125 =      2351.525 :: quick ratio factor
.    x 1.177 =      2767.032 :: short ratio factor
.    x 1.007 =      2785.574 :: price-to-book factor
.    x 1.049 =      2920.879 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.759 =      8059.391 :: sector+industry 1-year gains factor
.     x 1.01 =      8139.865 :: industry 12-weeks return factor
.    x 1.309 =     10658.066 :: industry 2-weeks return factor
.    x 0.984 =     10492.471 :: "drift" penalty 4 days ago
.    / 2.046 =      5128.136 :: overall "drift" factor
.    x 0.893 =        4577.7 :: largest single-day jump factor
.    x 0.066 =       304.166 :: low price factor
.    x 0.617 =       187.749 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.929 =       174.433 :: forward EPS factor
.    x 0.974 =       169.938 :: forward P/E factor
.    x 1.184 =       201.199 :: industry recommendation factor
.     x 2.42 =       486.855 :: company recommendation factor
.    x 1.002 =       487.594 :: factor historical industry gain for week 29
.    x 0.968 =        472.06 :: target low factor
.    x 1.312 =       619.497 :: target mean factor
.     x 1.05 =       650.734 :: target high factor
.    x 5.211 =       3390.75 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         7.631 :: reduced for readability
.   + 10.585 =        18.216 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     18.216 :: FINAL WEIGHT for NASDAQ:CLRB


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org